Multiple myeloma: open trials in Israel

35 open trials have a site in Israel. Registry data; only the trial team decides who can take part.

NCT05137054
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Trial Treatment · Phase 1 · Regeneron Pharmaceuticals
Rambam Health Care Campus, Haifa · Hadassah medical Center, Jerusalem · Sheba medical center, Ramat Gan
Registry updated 2026-11-05
NCT05927571
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Trial Treatment · Phase 1 · Genentech, Inc.
Rambam Health Care Campus, Haifa · Hadassah University Hospital - Ein Kerem, Jerusalem · The Chaim Sheba Medical Center - PPDS, Ramat Gan · Tel Aviv Sourasky Medical Center PPDS, Tel Aviv
Registry updated 2026-11-05
NCT06971380
Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis
Trial Treatment · Phase 2 · Polina Stepensky
Hadassah MO, Jerusalem
Registry updated 2026-11-04
NCT04634552
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 2 · Janssen Research & Development, LLC
Carmel Medical Center, Haifa · Rambam Medical Center, Haifa · Hadassah medical Center, Jerusalem · Sheba medical center, Ramat Gan · Tel-Aviv Sourasky Medical Center, Tel Aviv
Registry updated 2026-11-03
NCT05201781
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Trial Treatment · Phase 4 · Janssen Research & Development, LLC
Tel-Aviv Sourasky Medical Center, Tel Aviv
Registry updated 2026-11-03
NCT05552222
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
Soroka Medical Center, Beersheba · Rambam Medical Center, Haifa · Shaare Zedek Medical Center, Jerusalem · Rabin, Petah Tikva · Sheba medical center, Ramat Gan · Tel-Aviv Sourasky Medical Center, Tel Aviv
Registry updated 2026-11-03
NCT07258511
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
Soroka Medical Center, Beersheba · Rambam Medical Center, Haifa · Bnai Zion Medical Center, Haifa · Carmel Medical Center, Haifa · Shaare Zedek MC, Jerusalem · Sheba medical center, Ramat Gan · Baruch Padeh MC, Ramat Poriya · Assuta MC, Tel Aviv
Registry updated 2026-11-03
NCT07665450
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
Carmel Medical Center, Haifa · Rambam Med.Center - Hematology Institute, Haifa · Shaare Zedek Medical Center, Jerusalem · Rabin Medical Center, Petah Tikva · Sheba medical center, Ramat Gan · Tel-Aviv Sourasky Medical Center, Tel Aviv
Registry updated 2026-11-03
NCT05519085
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Trial Treatment · Phase 3 · Celgene
Haifa · Jerusalem · Kfar Saba · Peatch Tikva · Ramat Gan · Tel Aviv
Registry updated 2026-10-30
NCT04414475
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.
Trial Treatment · Phase 2 · Karyopharm Therapeutics Inc
Emek Medical Center, Afula · Assuta Ashdod Medical Center, Ashdod · Barzilai Medical Center, Ashkelon · Soroka University Medical Center, Beersheba · Bnai Zion Medical Center, Haifa · Rambam Health Care Campus, Haifa · Hadassah medical Center, Jerusalem · Shaare Zedek Medical Center, Jerusalem · Meir Medical Center, Kfar Saba · Rabin Medical Center- Beilinson Hospital, Petah Tikva · The Chaim Sheba Medical Center at Tel HaShomer, Ramat Gan · Tel-Aviv Sourasky Medical Center, Tel Aviv
Registry updated 2026-10-29
NCT06615479
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Trial Treatment · Phase 3 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Hadassah medical Center, Jerusalem · Sheba medical center, Ramat Gan · Sourasky Medical Center, Tel Aviv
Registry updated 2026-10-29
NCT05623020
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Trial Treatment · Phase 3 · Pfizer
Soroka Medical Center, Beersheba · Hadassah medical Center, Jerusalem · Rabin Medical Center, Petah Tikva · The Edmond and Lily Safra Children's Hospital; The Chaim Sheba Medical Center, Ramat Gan · Sourasky Medical Center, Tel Aviv
Registry updated 2026-10-27
NCT06953960
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Trial Treatment · Phase 1/2 · AbbVie
Rambam Health Care Campus- Haifa /ID# 271256, Haifa · Hadassah Medical Center-Hebrew University /ID# 271253, Jerusalem · Rabin Medical Center. /ID# 272073, Petah Tikva · The Chaim Sheba Medical Center /ID# 271251, Ramat Gan · Tel Aviv Sourasky Medical Center /ID# 271252, Tel Aviv
Registry updated 2026-10-27
NCT04910568
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 1 · Genentech, Inc.
Rambam Medical Center, Haifa · Sourasky Medical Centre, Tel Aviv
Registry updated 2026-10-20
NCT07409246
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
Trial Treatment · Phase 1 · AbbVie
Hadassah Medical Center-Hebrew University /ID# 278865, Jerusalem · The Chaim Sheba Medical Center /ID# 279065, Ramat Gan · Tel Aviv Sourasky Medical Center /ID# 279066, Tel Aviv
Registry updated 2026-10-20
NCT07874334
Phase 1a/b Study of GPRC5D CART Therapy in Relapsed/Refractory Multiple Myeloma and Light-chain Amyloidosis
Trial Treatment · Phase 1 · Hadassah Medical Organization
Hadassah MO, Jerusalem
Registry updated 2026-10-20
NCT06892522
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Trial Treatment · Phase 1/2 · AbbVie
Soroka Medical Center /ID# 271367, Beersheba · Rambam Health Care Campus- Haifa /ID# 271364, Haifa · Hadassah Medical Center-Hebrew University /ID# 271362, Jerusalem · Rabin Medical Center. /ID# 271365, Petah Tikva · The Chaim Sheba Medical Center /ID# 271366, Ramat Gan
Registry updated 2026-10-19
NCT07333430
Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma
Trial Treatment · Phase 1 · Hadassah Medical Organization
Hadassah MO, Jerusalem, 9574869, Jerusalem
Registry updated 2026-10-16
NCT05735704
Early Detection and Screening of Hematological Malignancies - SANGUINE
Research · JaxBio Ltd
Tel Aviv Sourasky Medical Center - TASMC, Tel Aviv
Registry updated 2026-10-15
NCT04643002
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
Trial Treatment · Phase 1/2 · Sanofi
Jerusalem · Ramat Gan · Tel Aviv
Registry updated 2026-10-13
NCT06980480
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Trial Treatment · Phase 3 · Takeda
Shaare Zedek Medical Center, Jerusalem
Registry updated 2026-10-13
NCT07555938
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Trial Treatment · Phase 3 · Hoffmann-La Roche
Rambam Health Care Campus, Haifa · Hadassah Ein Karem Hospital, Jerusalem · Chaim Sheba Medical Center, Ramat Gan · Ichilov-Sourasky Medical Center, Tel Aviv
Registry updated 2026-10-13
NCT05243797
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Trial Treatment · Phase 3 · European Myeloma Network B.V.
Soroka University Medical Center, Beersheba · Health Care Campus, Haifa · Hadassah medical Center, Jerusalem · Beilinson Hospital, Petah Tikva · Chaim Sheba Medical Center, Ramat Gan · Tel-Aviv Sourasky Medical Center, Tel Aviv
Registry updated 2026-10-07
NCT05730036
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Trial Treatment · Phase 3 · Regeneron Pharmaceuticals
Lady Davis Carmel Medical Center, Haifa · Rambam Health Care Campus, Haifa · Shaare Zedek Medical Center, Jerusalem · Hadassah medical Center, Jerusalem · Sheba medical center, Ramat Gan · The Tel Aviv Sourasky Medical Center, Tel Aviv
Registry updated 2026-10-07
NCT06515249
Integrative Therapies in Multiple Myeloma
Trial Treatment · Bnai Zion Medical Center
Bnai Zion Medical Center, Haifa
Registry updated 2026-09-30

All Multiple myeloma trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error